Results 11 to 20 of about 838,442 (361)
Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology.
The Journal of the National Comprehensive Cancer Network, 2023 Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by the clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and/or other tissues.
D. Pollyea +36 more
semanticscholar +1 more source
Acute myeloid leukemia: update in diagnosis and treatment in Brazil [PDF]
Einstein (São Paulo), 2011 Objective: To identify how the Brazilian hematology centers treated and diagnosed cases of acute myeloid leukemia in 2009. Methods: An epidemiological observational multicenter study of 11 listed Brazilian centers that treat acute myeloid leukemia and ...
Ricardo Helman +12 more
doaj +3 more sources
Nature Medicine, 2022 The treatment landscape of acute myeloid leukemia (AML) is evolving, with promising therapies entering clinical translation, yet patient responses remain heterogeneous, and biomarkers for tailoring treatment are lacking.
Andy G. X. Zeng +18 more
semanticscholar +1 more source
Acute myeloid leukemia: current progress and future directions
Blood Cancer Journal, 2021 Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML) is occurring rapidly. Since 2017, nine agents have been approved for various indications in AML.
H. Kantarjian +8 more
semanticscholar +1 more source
Methods in Molecular Biology, 2018 Acute myeloid leukemia (AML) occurs with a frequency of 3.5/1,000,000/year cases. AML patients have an invasion of diseased cells (blasts) medullary insufficiency, microenvironmental dysfunction, defects in the proliferation and function of the remaining
Gert J. Ossenkoppele
semanticscholar +1 more source
Advances in acute myeloid leukemia
British medical journal, 2021 Acute myeloid leukemia (AML) is an uncommon but potentially catastrophic diagnosis with historically high mortality rates. The standard of care treatment remained unchanged for decades; however, recent discoveries of molecular drivers of leukemogenesis ...
Laura F. Newell, R. Cook
semanticscholar +1 more source
A dual origin for Bcr-Abl gene translocation/fusion as dynamics of synergism of the hematopoietic stem cell and hemangioblast in chronic myeloid leukemia [PDF]
, 2015 Contextual BCR-ABL tyrosine kinase over-activity determines in formulated fashion the emergence of proliferation and anti-apoptosis that arise largely as derived phenomena of otherwise homeostatic mechanisms of the c-ABL gene within hematopoietic ...
Agius, Lawrence M.
core +1 more source
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
Leukemia, 2020 The therapeutic landscape of chronic myeloid leukemia (CML) has profoundly changed over the past 7 years. Most patients with chronic phase (CP) now have a normal life expectancy.
A. Hochhaus +33 more
semanticscholar +1 more source
Haematologica, 2019 Differentiation therapies achieve remarkable success in acute promyelocytic leukemia, a subtype of acute myeloid leukemia. However, excluding acute promyelocytic leukemia, clinical benefits of differentiation therapies are negligible in acute myeloid ...
Jianbiao Zhou +13 more
doaj +1 more source
NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021.
The Journal of the National Comprehensive Cancer Network, 2021 The NCCN Guidelines for Acute Myeloid Leukemia (AML) provide recommendations for the diagnosis and treatment of adults with AML based on clinical trials that have led to significant improvements in treatment, or have yielded new information regarding ...
D. Pollyea +33 more
semanticscholar +1 more source